Chengdu Olymvax Biopharmaceuticals (SH:688319) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2026-01-05 16:51Core Viewpoint - Chengdu Olin Biotechnology Co., Ltd. has signed a market promotion service agreement with Keyuan Xinhai (Beijing) Medical Supplies Trading Co., Ltd. for the A group C group meningococcal polysaccharide conjugate vaccine, indicating a commitment to long-term cooperation and market expansion [2][4]. Agreement Overview - The agreement allows Keyuan Trading to exclusively promote the AC conjugate vaccine nationwide from 2024 to 2026, with a total promotion task of 4 million doses [4][5]. - A supplementary agreement has been signed to extend the original contract period from December 31, 2026, to December 31, 2029, while maintaining other core terms unchanged [5][6]. Impact on Company Performance - The signing of the agreement is not expected to have a significant impact on the company's current operating performance [3][7]. - The projected sales volume for the AC conjugate vaccine in 2024 is 252,000 doses, but there is uncertainty regarding the actual sales performance due to market conditions [7].